Scarica l'app Stockscreener
3.51
0.57%
-0.02
Pre-mercato:
3.41
-0.10
-2.85%
Soligenix Inc Borsa (SNGX) Ultime notizie
Soligenix Announces Formation of European Medical Advisory Board for Cutaneous T-Cell Lymphoma - Nasdaq
Soligenix Trumpets Q2 Numbers - MENAFN.COM
Soligenix to Present at Q4 Investor Summit: Rare Disease Treatment Pipeline in Focus | SNGX Stock News - StockTitan
Brokers Offer Predictions for Soligenix FY2024 Earnings - Defense World
Soligenix Kickstarts Dusquetide Mid-Stage Study For Patients With Inflamed Blood Vessels - AOL
Soligenix Initiates A Phase 2 Clinical Trial of SGX945 for the Treatment of Behcet's Disease - Marketscreener.com
Soligenix Initiates a Phase 2 Clinical Trial of SGX945 (dusquetide) for the treatment of Behçet's Disease - Nasdaq
SNGX: Phase 3 CTCL Trial to Initiate Before End of 2024 - MSN
Soligenix Third Quarter 2024 Earnings: US$0.78 loss per share (vs US$2.56 loss in 3Q 2023) - Yahoo Finance
Soligenix Inc. (SNGX) Quarterly 10-Q Report - Quartz
SEC Form 424B3 filed by Soligenix Inc. - Quantisnow
Soligenix Announces Recent Accomplishments And Third Quarter 2024 Financial Results - citybiz
Soligenix Reports Q3 Loss, Advances Clinical Pipeline with $9.8M Cash Position | SNGX Stock News - StockTitan
Soligenix Granted FDA Orphan Drug Designation For SuVax Active Ingredient - Contract Pharma
Oral Mucositis Market Forecasted to Surge in Coming Years, - openPR
Soligenix, Inc. to Present at the 2024 ThinkEquity Conference - GlobeNewswire
Soligenix gains Hong Kong patent for synthetic hypericin - Investing.com India
Soligenix to Present at Upcoming Conferences - GuruFocus.com
Soligenix gains Hong Kong patent for synthetic hypericin By Investing.com - Investing.com Nigeria
Oral Mucositis Market Forecasted to Surge in Coming Years, 2024-2034 Analysis by DelveInsight | Swedish Orphan Biovitrum, Galera Therapeutics, EpicentRx, Galera Therapeutics, Inc., Soligenix - Barchart
Soligenix Receives Hong Kong Patent for Improved Production of Synthetic Hypericin - Lelezard
Soligenix Invited to Present at Upcoming Investor Conferences - StockTitan
Soligenix secures amended loan terms with Pontifax Medison - Investing.com India
Soligenix secures amended loan terms with Pontifax Medison By Investing.com - Investing.com UK
HyBryte™ Expanded Treatment Results to be Presented at the European Organisation for Research and Treatment of Cancer Conference - PR Newswire
Soligenix, Inc. Announces HyBryte Expanded Treatment Results to Be Presented at the European Organisation for Research and Treatment of Cancer Conference - Marketscreener.com
A stock that deserves closer examination: Soligenix Inc (SNGX) - US Post News
Soligenix partners with Sterling to scale hypericin production By Investing.com - Investing.com Australia
SNGX: Marburg Outbreak Puts Focus on Soligenix Vaccine Development - Research Tree
SNGX: Marburg Outbreak Puts Focus on Soligenix Vaccine Development… - Zacks Small Cap Research
Soligenix partners with Sterling to scale hypericin production - Investing.com India
Soligenix Announces Partnership with Sterling Pharma Solutions - Lelezard
Indo-Asian News Service-SOLIGENIX ANNOUNCES PARTNERSHIP WITH STERLING PHARMA SOLUTIONS - IANS India Pvt Ltd
Join Soligenix's Exclusive Live Investor Webinar and Q&A Session on September 18, 2024 - cnhinews.com
Nova Minerals and Soligenix Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - AccessWire
Swvl expands Saudi Arabia presence with new contracts By Investing.com - Investing.com Canada
Southern (NYSE:SO) Lowered to “Neutral” at Mizuho - Defense World
Luna Aura introduces Sofia Andres as first celebrity endorser for Hope Glow Super Glutathione Capsules - LionhearTV
0.69%
6.90%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):